Vincristine, DOXIL® (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Condition(s) targeted: Myeloma Proteins; Multiple Myeloma; Myeloma; M-Protein

Intervention: Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD) (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Official(s) and/or principal investigator(s):
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

The purpose of this study is to determine how well newly diagnosed multiple myeloma patients respond to an experimental regimen of Vincristine, DOXIL (doxorubicin HCl liposome injection) and Dexamethasone (VDD) versus the standard treatment of Vincristine, Doxorubicin and Dexamethasone (VAD).

Official title: A Multi-Center Randomized Study of Vincristine, Doxil® and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Multiple Myeloma

Study design: Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study

Primary outcome: To determine and compare the objective response rate (the percentage of patients who attain an Objective Status of Complete Remission, Remission or Partial Remission) for patients receiving VDD vs VAD.

Secondary outcome: To evaluate and compare the clinical benefit of VDD vs VAD for the following measures: Hospitalization, Documented sepsis,Antibiotic use, Grade 3 or 4 neutropenia or neutropenic fever

Detailed description: This is a randomized, open label study comparing the efficacy, clinical benefit, toxicity and safety of the combination of Vincristine, DOXIL® (doxorubicin HCl liposome injection), and Dexamethasone (VDD) to the standard regimen of Vincristine, Doxorubicin and Dexamethasone (VAD) in patients with newly diagnosed multiple myeloma. Approximately 200 patients with newly diagnosed multiple myeloma will be randomized to receive either VDD or VAD. This study will determine and compare the objective response rate (the percentage of patients who attain an Objective Status of Complete Remission, Remission or Partial Remission) for patients receiving VDD vs. VAD. This study will also evaluate and compare the clinical benefit of VDD vs. VAD for the following measures: Hospitalization; Documented sepsis; Antibiotic use; Grade 3 or 4 neutropenia or neutropenic fever.

VDD: Vincristine 1. 4 mg/m2 IV on Day 1; Doxil® 40 mg/m2 IV on Day 1; Dexamethasone 40 mg/day oral Days 1-4; VAD: Vincristine 0. 4 mg/day continuous infusion Days 1-4; Doxorubicin 9. 0 mg/m2/day continuous infusion Days 1-4; Dexamethasone 40 mg/day orally on Days 1-4; Every 28 days for 4 cycles

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Untreated multiple myeloma requiring treatment

- Total cumulative dose of prior doxorubicin can not exceed 240 mg/m2

- Must have measurable disease

- Left Ventricular Ejection Fraction (LVEF) >= 50 % determined by Multiple Gated

Acquisition Scan (MUGA)

- Karnofsky performance status of >= 60%

- Adequate bone marrow, liver and renal function

- Disease-free from prior malignancies >= 5 years with the exception of basal cell or

squamous cell carcinoma of the skin or carcinoma in situ of the cervix

- Female participants (if of child bearing potential and sexually active) and male

participants (if sexually active with a partner of child-bearing potential) must use medically acceptable methods of birth control

Exclusion Criteria:

- Life expectancy of >= 3 months

- Pregnant or breast feeding

- History of cardiac disease, with New York Heart Association Class II or greater, with

congestive heart failure

- Or unstable angina, uncontrolled hypertension or cardiac arrythmias or myocardial

infarction within the last 6 months

- Uncontrolled diabetes mellitus or systemic infection

- Nonsecretory myeloma, Monoclonal Gammopathy of Unknown Significance (MGUS) or

smoldering myeloma

- Confusion, disorientation, or history of psychiatric illness which may impair

patient's ability to give informed consent

- Prior chemotherapy to treat Multiple Myeloma

- Prior radiotherapy to an area greater than 1/3 of the skeleton

- Prior local radiotherapy within 1 week of treatment

- Any investigational agent within 30 days of the first dose of treatment

- Prior single agent dexamethasone (or another corticosteroid) to treat Multiple

Myeloma

A Multi-Center Randomized Study of Vincristine, DOXIL and Dexamethasone vs. Vincristine Doxorubicin, and Dexamethasone in Patients with Multiple Myeloma

Starting date: October 2000
Ending date: June 2004
Last updated: March 17, 2008